Creative Biolabs combines deep, industry-leading expertise with innovative platforms to provide cutting-edge AsPC-1 engineering service for pancreatic cancer cell self-destruction purposes.

Therapy of Pancreatic Cancer

Despite tremendous effort and progress in the diagnostics of pancreatic cancer with respect to imaging techniques and molecular genetics. The incidence of pancreatic cancer has been increasing while its 5-year survival of around 4-6% has not changed in decades. Current chemotherapy regimens have modest survival benefits. Although newer agents are being tested in pancreatic cancer patients. In the era of personalized medicine, immunotherapy has emerged as a promising treatment modality Nevertheless, although immunotherapy has shown brilliant results across a wide range of malignancies, only a few antibodies have been approved for use in patients with pancreatic cancer. New personalized immunotherapies for the treatment of pancreatic cancer are still needed.

Fig.1 Illustrations of chimeric antigen receptor T cells immunotherapy. (Jai, et al., 2021)

Pancreatic Cancer Cell AsPC-1 Engineering Service at Creative Biolabs

AsPC-1 is a cell line derived from nude mouse xenografts initiated with cells from the ascites of a 62-year-old woman with adenocarcinoma of the head of the pancreas and metastases to several abdominal organs. The patient received radiation and chemotherapy but eventually developed ascites and died two weeks later. The ascitic cell culture was noted to produce abundant mucin as well as carcinoembryonic antigen. This cell line is useful in pancreatic cancer research.

With an experienced team in inspiring the lymphangiogenic potentiation of immunotherapy to Turning Cancer Cells Against Themselves, the pancreatic cell lines AsPC-1 could be engineered into Cytokine Overexpression cells for cancer cell self-destruction purposes. Our seasoned scientists will work with you to develop a complete solution for your special needs.

Our strategies for engineering cancer cells for self-destruction include but are not limited to:

• Engineering Cancer Cells with Target-specific Aptamer for Cancer Immunotherapy
• Engineering Cancer Cells with Aptamer-siRNA for Enhanced Antitumor T Cell Immunity
• Engineering Cancer Cells with Synthetic Immunomodulatory Gene Circuits for Cancer Immunotherapy
• Engineering Cancer Cells with Targeted siRNA Delivery for Cancer Immunotherapy

What's more, we are proficient at performing Ex Vivo Immune Reactivity Assessment and Toxicity Assessment of self-destruction cancer cells by several efficient approaches. Our methods for ex vivo immune reactivity assessment include Cytokine Production Measurement and Chemokine Production Measurement.

Our methods for Toxicity assessment of self-destruction cancer cells include but are not limited to:

• Quantification of Alanine Aminotransferase (ALT)
• Quantification of Alkaline Phosphate (ALP)
• Quantification of Amylase
• Quantification of Calcium
• Quantification of Glucose
• Quantification of Cholesterol
• Quantification of Electrolyte
• Quantification of Creatinine Kinase
• Quantification of Total Bilirubin
• Quantification of Total Protein

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Jai, Hoon Yoon.; et al. Immunotherapy for pancreatic cancer. World J Clin Cases. 2021, 9(13): 2969-2982.

For Research Use Only | Not For Clinical Use